{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:46:08Z","timestamp":1793389568287,"version":"4.5.0"},"reference-count":39,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2024.2023.0430","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T01:21:02Z","timestamp":1709515262000},"page":"26-36","source":"Crossref","is-referenced-by-count":11,"title":["Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients"],"prefix":"10.4274","author":[{"given":"Zehra","family":"Narl\u0131 \u00d6zdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u0131ld\u0131z","family":"\u0130pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pusem","family":"Patir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6zde","family":"Ermi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafiye","family":"\u00c7ift\u00e7iler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Y\u0131ld\u0131zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tar\u0131k","family":"Ercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayfun","family":"Elibol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Mersin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylem","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren Arslan","family":"Davulcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Karaku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergiz","family":"Erkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrsel","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan","family":"Diz K\u00fc\u00e7\u00fckkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","unstructured":"1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.","journal-title":"N Engl J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","unstructured":"2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","unstructured":"3. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 2016;91:390-394.","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","unstructured":"4. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-1551.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bjh.13076","article-title":"CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients","volume":"168","author":"Trifa","year":"2015","unstructured":"5. Trifa AP, Popp RA, Cucuianu A, B\u0103nescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, C\u00e2ndea M, Militaru MS, Pop IV. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol 2015;168:151-153.","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","unstructured":"6. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016;127:1307-1316.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.3390\/ijms22073371","article-title":"The contemporary approach to CALR-positive myeloproliferative neoplasms","volume":"22","author":"Bel\u010di\u010d Miki\u010d","year":"2021","unstructured":"7. Bel\u010di\u010d Miki\u010d T, Paji\u010d T, Zver S, Sever M. The contemporary approach to CALR-positive myeloproliferative neoplasms. Int J Mol Sci 2021;22:3371.","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","unstructured":"8. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, M\u00fcllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179-3184.","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A. Mayo CALR mutation type classification guide using alpha helix propensity. Am J Hematol 2018;93:E128-E129.","DOI":"10.1002\/ajh.25065"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","unstructured":"10. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014;89:121-124.","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","unstructured":"11. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 2019;94:599-610.","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","unstructured":"12. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-2513.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","unstructured":"13. Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol 2018;93:1474-1484.","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","unstructured":"14. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, M\u00fcllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-1201.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","unstructured":"15. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405.","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","unstructured":"16. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/bjh.16988","article-title":"Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia","volume":"192","author":"Alvarez-Larr\u00e1n A","year":"2021","unstructured":"17. Alvarez-Larr\u00e1n A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa G\u00f3mez-Casares M, Cuevas B, Caballero G, Garc\u00eda-Hern\u00e1ndez C, Garc\u00eda-Guti\u00e9rrez V, Palomino A, Ferrer-Mar\u00edn F, Isabel Mata-V\u00e1zquez M, Moret\u00f3 A, Magro E, Murillo I, Manuel Alonso-Dom\u00ednguez J, Mar\u00eda Guerra J, Guerrero L, Mar\u00eda Raya J, P\u00e9rez-Encinas M, Carre\u00f1o-Tarragona G, Fox L, Pastor-Gal\u00e1n I, Bellosillo B, Hern\u00e1ndez-Boluda JC; MPN Spanish Group (GEMFIN). Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Br J Haematol 2021;192:988-996.","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","unstructured":"18. Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 2015;100:893-897.","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","unstructured":"19. Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 2016;91:503-506.","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","unstructured":"20. Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP, Hanson CA, Pardanani A, Gangat N, Wolanskyj AP. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28:2300-2303.","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10245332.2016.1252003","article-title":"JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia","volume":"22","author":"Wang","year":"2017","unstructured":"21. Wang J, Zhang B, Chen B, Zhou RF, Zhang QG, Li J, Yang YG, Zhou M, Shao XY, Xu Y, Xu XH, Ouyang J, Xu J, Ye Q. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. Hematology 2017;22:145-148.","journal-title":"Hematology"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Abdelghani M, Hammami H, Zidi W, Amouri H, Othmen HBH, Farrah A, Menif S. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia. J Clin Lab Anal 2022;36:e24522.","DOI":"10.1002\/jcla.24522"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Ceylan C, Ozyilmaz B, Kirbiyik O, Ugur MC, Ozer O. JAK2V617F, CALR and MPL515L\/K mutations and plateletcrit in essential thrombocythemia: a single centre's experience. Int J Clin Pract 2021;75:e13834.","DOI":"10.1111\/ijcp.13834"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","unstructured":"24. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33:313-320.","journal-title":"Semin Thromb Hemost"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","unstructured":"25. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:1599-1613.","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ejh.12389","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"94","author":"Gangat","year":"2015","unstructured":"26. Gangat N, Wassie EA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Passamonti F, Tefferi A. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol 2015;94:31-36.","journal-title":"Eur J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-021-00470-y","article-title":"Mutations and thrombosis in essential thrombocythemia","volume":"11","author":"Guglielmelli","year":"2021","unstructured":"27. Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, Morsia E, Sordi B, Szuber N, Hanson CA, Pardanani A, Vannucchi AM, Tefferi A. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J 2021;11:77.","journal-title":"Blood Cancer J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4274\/tjh.galenos.2021.2021.0607","article-title":"JAK2V617F-positive endothelial cells induce apoptosis and release JAK2V617F-positive microparticles","volume":"39","author":"Hekimo\u011flu","year":"2022","unstructured":"28. Hekimo\u011flu H, Toprak SF, S\u00f6zer S. JAK2V617F-positive endothelial cells induce apoptosis and release JAK2V617F-positive microparticles. Turk J Hematol 2022;39:13-21.","journal-title":"Turk J Hematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/medicina58121798","article-title":"Essential thrombocythemia: one-center data in a changing disease","volume":"58","author":"Pirciulescu","year":"2022","unstructured":"29. Pirciulescu N, Gaman MA, Mihailescu M, Constantin C, Dragomir M, Dobrea C, Costache S, Ursuleac I, Coriu D, Crisan AM. Essential thrombocythemia: one-center data in a changing disease. Medicina (Kaunas) 2022;58:1798.","journal-title":"Medicina (Kaunas)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","unstructured":"30. Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 2015;100:46-48.","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","unstructured":"31. Cervantes F, Alvarez-Larr\u00e1n A, Talarn C, G\u00f3mez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-790.","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","unstructured":"32. Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM. Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients. Am J Hematol 2017;92:1193-1197.","journal-title":"Am J Hematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","unstructured":"33. Sen\u00edn A, Fern\u00e1ndez-Rodr\u00edguez C, Bellosillo B, Camacho L, Longar\u00f3n R, Angona A, Besses C, \u00c1lvarez-Larr\u00e1n A. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol 2018;97:443-451.","journal-title":"Ann Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","unstructured":"34. Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol 2020;189:291-302.","journal-title":"Br J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"100714","DOI":"10.1016\/j.blre.2020.100714","article-title":"Current management strategies for polycythemia vera and essential thrombocythemia","volume":"42","author":"Guglielmelli","year":"2020","unstructured":"35. Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020;42:100714.","journal-title":"Blood Rev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"CN","year":"2005","unstructured":"36. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","unstructured":"37. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-1728.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1517\/14656566.2013.799140","article-title":"The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment","volume":"14","author":"Haznedaroglu","year":"2013","unstructured":"38. Haznedaroglu IC. The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert Opin Pharmacother 2013;14:1431-1436.","journal-title":"Expert Opin Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","unstructured":"39. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117:5857-5859.","journal-title":"Blood"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:15:21Z","timestamp":1710476121000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-45538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":39,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2023.0430","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}